Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds
View Patent ↗Inhibitors of mTOR, MEK, JAK and PI3K and compositions containing the same are disclosed. Methods of using the inhibitors in the treatment of a variety of diseases and conditions wherein inhibition of one or more of mTOR, MEK, JAK and PI3K provides a benefit also are disclosed. Methods of using chemical attachment moieties and linkers for the purposes of modifying compound solubility and/or lymphatic absorption are also disclosed.
1. An MEK inhibitor selected from the group consisting of
2. A method of treating a disease or condition wherein inhibition of MEK provides a benefit comprising administering a therapeutically effective amount of a compound of claim 1 to an individual in need thereof.
3. The method of claim 2 wherein the disease or condition is selected from the group consisting of
a cancer;
a pulmonary disease, a fibrotic disorder, an inflammatory disorder, chronic pain, and a neurodegenerative disease; and
a chronic obstructive pulmonary disease, IPF, an autoimmune disease, multiple sclerosis, and Alzheimer's disease.